Microorganism Of The Genus Escherichia Is A Host For The Plasmid Or Episome Patents (Class 435/488)
  • Patent number: 10653794
    Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
  • Patent number: 10450560
    Abstract: There is disclosed a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there is disclosed a process for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, “on device” assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: October 22, 2019
    Assignee: Gen9, Inc.
    Inventor: Andrew V. Oleinikov
  • Patent number: 10253074
    Abstract: A mutant strain of the bacterium Clostridium botulinum having an inactivated botulinal neurotoxin gene is disclosed. The mutant strain contains an artificially created and inserted modified intron vector between nucleotides 580 and 581 of the sense strand of the gene. The mutant strain can be used in microbiological challenge testing of foods and food processing methods.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: April 9, 2019
    Assignee: Wisonsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Marite Bradshaw, Kristin M. Marshall
  • Patent number: 9975926
    Abstract: This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the FMDV capsid polyprotein precursor into a plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 22, 2018
    Assignee: The United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max Rasmussen, John Neilan
  • Patent number: 8945885
    Abstract: The present invention provides minicircle nucleic acid vector formulations for use in administering to a subject, wherein the minicircle nucleic acid vectors include a polynucleotide of interest, a product hybrid sequence of a unidirectional site-specific recombinase, and are devoid of plasmid backbone bacterial DNA sequences. Also provided are methods of producing the subject formulations as well as methods for administering the minicircle nucleic acid vector formulations to a subject. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhi-Ying Chen, Mark A. Kay
  • Patent number: 8927231
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 6, 2015
    Assignees: The Board of Trustees of the University of Arkansas, University of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventors: Ellen M. Brune, Robert R. Beitle, Jr., Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Patent number: 8895310
    Abstract: The present invention relates to methods for expressing nucleic acid sequences in prokaryotic host cells, where at least one DNA construct which is capable of episomal replication in a host cell and which comprises a nucleic acid sequence to be expressed under the transcriptional control of an L-rhamnose-inducible promoter, where the promoter is heterologous with regard to the nucleic acid sequence, is introduced into the host cell and the expression of he nucleic acid sequence is induced by addition of L-rhamnose, wherein the prokaryotic host cell is at least deficient with regard to an L-rhamnose isomerase.
    Type: Grant
    Filed: November 27, 2003
    Date of Patent: November 25, 2014
    Assignee: BASF SE
    Inventors: Maria Keβeler, Thomas Zelinski, Bernhard Hauer
  • Patent number: 8884100
    Abstract: Nucleic acid molecules from Cannabis sativa (cannabis, hemp, marijuana) have been isolated and characterized, and encode polypeptides having aromatic prenyltransferase activity. Specifically, the enzyme, CsPT1, is a geranylpyrophosphate olivetolate geranyltransferase, active in the cannabinoid biosynthesis step of prenylation of olivetolic acid to form cannabigerolic acid (CBGA). Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: November 11, 2014
    Assignees: National Research Council of Canada, University of Saskatchewan
    Inventors: Jonathan E. Page, Zakia Boubakir
  • Patent number: 8871491
    Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: October 28, 2014
    Assignee: Glycovaxyn AG
    Inventors: Michael Wacker, Michael Kowarik, Michael Wetter
  • Patent number: 8852911
    Abstract: The present disclosure provides a method for producing a Dicer polypeptide in a prokaryotic host cell. The present disclosure further provides a purified Dicer complex. The present disclosure further provides kits for producing a Dicer polypeptide in a prokaryotic host cell.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: October 7, 2014
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Enbo Ma
  • Patent number: 8796235
    Abstract: The present invention pertains to vectors for regulating gene expression having at least one gene expressing cassette and at least one gene suppressing cassette, wherein the gene expression cassette encodes a polypeptide of interest, and wherein the gene suppressing cassette encodes a short interfering RNA (siRNA) molecule that reduces expression of a target gene by RNA interference. The present invention further includes vectors that contain suppressor cassettes in conjunction with cassettes upregulating gene expression regulated by either a constitutive promoter, such as a general CMV promoter, or a tissue specific promoter. The present invention further includes vectors that contain Dengue virus gene suppression cassettes. The present invention further includes pharmaceutical compositions containing such vectors, methods of modulating the expression of genes in a host using such vectors, and method of producing such vectors.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 5, 2014
    Assignee: University of South Florida
    Inventors: Shyam S. Mohapatra, Weidong Zhang
  • Patent number: 8778683
    Abstract: The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: July 15, 2014
    Assignee: UVic Industry Partnerships Inc.
    Inventor: Francis E. Nano
  • Patent number: 8753864
    Abstract: The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), nucleic acids encoding these proteins as well as corresponding vectors and host cells. In addition, the present invention is directed to the use of said proteins, nucleic acids, vectors and host cells for preparing medicaments. Furthermore, the present invention provides methods for producing said proteins.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: June 17, 2014
    Assignee: ETH Zurich
    Inventors: Markus Aebi, Michael Kowarik, Umesh Ahuja
  • Publication number: 20140154742
    Abstract: The present invention relates to a recombinant DNA expression/secretion system in E. coli wherein the said system combines the potential of signal peptide-based translocation of recombinant proteins to the periplasmic space of E. coli with membrane brave defective mutants of E. coli to further aid secretion into the extracellular space. The present invention further relates to the expression system which furthermore includes a helper plasmid to drive the expression of translocons to facilitate improved periplasmic secretion of the over-expressed recombinant protein. In addition, this system also facilitates efficient production of specific proteins of interest in E. coli.
    Type: Application
    Filed: April 8, 2012
    Publication date: June 5, 2014
    Applicant: ANTHEM BIOSCIENCES PVT LTD.
    Inventors: Ayyappan Nair, Sunil Kumar Sukumaran, Shalaka Samant, Gunja Gupta, Suthakarn Pichaimuthu, Ganesh Sambasivam
  • Patent number: 8669073
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: March 11, 2014
    Assignee: The Scripps Research Institute
    Inventors: J. Christopher Anderson, Ning Wu, Stephen Santoro, Peter G. Schultz
  • Patent number: 8618355
    Abstract: Nucleic acid molecules from hop (Humulus lupulus) have been isolated and characterized wherein said nucleic acid molecules encode polypeptides having aromatic prenyltransferase activity Expression or over-expression of said nucleic acid molecules alters the level of terpenophenolic compounds The polypeptides may be used in vivo or in vitro to produce terpenophenolic compounds (e g, prenylated acylphloroglucmols and prenylflavonoids) such as prenyl-PIVP, prenyl-PIBP, humulone, lupulone, desmethylxanthohumol and xanthohumol.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: December 31, 2013
    Assignee: National Research Council of Canada
    Inventors: Jonathan Page, Enwu Liu, Jana Nagel
  • Patent number: 8592199
    Abstract: The present invention relates to a method to engineer either the genome of a genetically modified organism, other bioengineered reagent, or in vitro translation system for protein synthesis from specific protein-coding genes so that the protein-coding genes so engineered can only produce proteins with an intended structure when translated within the context of that specifically engineered GMO or in vitro translation system. It also relates to nucleic acids for use in such GMOs or translation systems.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: November 26, 2013
    Inventor: David H. Ardell
  • Publication number: 20130224865
    Abstract: Novel antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells and is prevented from occurring in donor cells. Another type kills recipient bacteria by expressing a gene that produces a product detrimental or lethal to recipient bacterial cells, that gene being prevented from expression in donor cells.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 29, 2013
    Inventor: Wisconsin Alumni Research Foundation
  • Patent number: 8497096
    Abstract: The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: July 30, 2013
    Assignee: XOMA Technology Ltd.
    Inventor: Arnold Horwitz
  • Patent number: 8476041
    Abstract: A method is disclosed for restoring a Glu+ phenotype to a PTS?/Glu? bacterial cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport. Bacterial cells comprising the Glu+ phenotype have modified endogenous chromosomal regulatory regions which are operably linked to polynucleotides encoding galactose permeases and glucokinases.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: July 2, 2013
    Assignee: Danisco US Inc.
    Inventors: Marguerite A. Cervin, Philippe Soucaille, Fernando Valle, Gregory M. Whited
  • Publication number: 20130149785
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Application
    Filed: November 19, 2012
    Publication date: June 13, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: The Johns Hopkins University
  • Publication number: 20130130340
    Abstract: Microorganisms are genetically engineered to synthesize caffeic acid from simple carbon sources via a tyrosine intermediate by means of a dual pathway that utilizes both endogenous and engineered enzymatic activities.
    Type: Application
    Filed: November 6, 2012
    Publication date: May 23, 2013
    Applicants: UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Yajun YAN, Yuheng LIN
  • Publication number: 20130115658
    Abstract: The present invention is related to integrated method and tools to construct recombinant DNA molecules (to be used as DNA vaccine or gene therapy) without requiring the use of antibiotic(s) resistance gene(s) and without requiring the addition of one or more antibiotic(s) to the culture medium of cells submitted to this recombinant DNA method. The present invention allows to obtain the selection of recombinant host cell(s) transformed by a (exogenous) nucleic acid sequence of interest (extra-chromosomal vector containing the insert) and simultaneously stabilization (stable inheritance) of this (exogenous) nucleic acid sequence of interest into the transformed host cell(s) descendants (maintenance of the nucleic acid sequence of interest in the host cells population).
    Type: Application
    Filed: October 25, 2012
    Publication date: May 9, 2013
    Inventors: Cédric Szpirer, Michel C. Milinkovitch, Philippe Gabant
  • Publication number: 20130102077
    Abstract: Alterations utilizing nanoparticles. Certain embodiments of the invention are methods of delivering a substance to a target using a delivery-aid which includes nanoparticles. Those nanoparticles may be nanocarbon particles. Other embodiments are methods of delivering nanoparticles to a target involving placing a mask between a source of ballistic delivery of nanoparticles and the target. Other embodiments include irradiating a target to cause localized heating of the region of the target in which the nanodiamonds or OLC particles are present. Other embodiments utilize nanoparticles to make cells competent for genetic transformation. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 25, 2013
    Applicant: International Technology Center
    Inventors: Varvara Grichko, Olga Alexander Shenderova
  • Publication number: 20130095524
    Abstract: The present invention provides a novel method of producing a recombinant bacterium for production of a non-natural protein, including: (1) expressing tRNA in a bacterium, which tRNA recognizes UAG codon; (2) expressing an aminoacyl-tRNA synthetase in the bacterium, which aminoacyl-tRNA synthetase acylates the tRNA with a non-natural amino acid or an ?-hydroxy acid; (3) (i) introducing a DNA construct into the bacterium, which DNA construct is for expressing, in the absence of a release factor for terminating translation at UAG codon, a function of at least one gene selected from the group consisting of genes each of which loses its function when a gene that codes for the release factor is defective and/or introducing an alteration into said at least one gene in a chromosome of the bacterium, which alteration is for expressing the function of said at least one gene in the absence of the release factor; and (4) causing the gene that codes for the release factor in the bacterium to be defective.
    Type: Application
    Filed: June 16, 2011
    Publication date: April 18, 2013
    Applicant: RIKEN
    Inventors: Shigeyuki Yokoyama, Takahito Mukai, Kensaku Sakamoto, Akiko Matsumoto
  • Publication number: 20120238024
    Abstract: Novel antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells and is prevented from occurring in donor cells. Another type kills recipient bacteria by expressing a gene that produces a product detrimental or lethal to recipient bacterial cells, that gene being prevented from expression in donor cells.
    Type: Application
    Filed: April 16, 2012
    Publication date: September 20, 2012
    Inventor: Marcin S. Filutowicz
  • Patent number: 8242244
    Abstract: This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: August 14, 2012
    Assignee: The Scripps Research Institute
    Inventors: Zhiwen Zhang, Lital Alfonta, Peter Schultz
  • Patent number: 8217145
    Abstract: The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the unnatural amino acid phenylselenocysteine into proteins produced in eubacterial host cells such as E. coli. The invention provides, for example but not limited to, novel orthogonal aminoacyl-tRNA synthetases, polynucleotides encoding the novel synthetase molecules, methods for identifying and making the novel synthetases, methods for producing proteins containing the unnatural amino acid phenylselenocysteine and translation systems. The invention further provides methods for producing modified proteins (e.g., lipidated proteins) through targeted modification of the phenylselenocysteine residue in a protein.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: July 10, 2012
    Assignee: The Scrips Research Institute
    Inventors: Jiangyun Wang, Peter G. Schultz
  • Patent number: 8211648
    Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: July 3, 2012
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Christopher R. Bebbington
  • Patent number: 8187842
    Abstract: The invention provides microbial strains possessing improved properties for production of aspartate-derived amino acids and chemicals. Methods of making such strains are provided. These methods include altering expression of the aceBAK operon, the glcB gene, or both. Alteration of expression may be accomplished through increased transcription, relief from native transcriptional control, and/or other means. Replacement of native promoters for these genes is also contemplated; for instance, their native promoters may be replaced by the tac promoter (Ptac).
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: May 29, 2012
    Assignee: Archer Daniels Midland Company
    Inventors: John N. D'Elia, Sean W. Jordan
  • Publication number: 20120082648
    Abstract: Escherichia coli strains, such as enterotoxigenic E. coli strains, genetically engineered to express from recombinant plasmids one or more colonization factors (CFs) associated with enterotoxigenic Escherichia coli bacteria (ETEC) in an increased amount compared to said CFs expressed by ETEC wild-type reference strains, as well as a method of producing such strains, and vaccine compositions against diarrhea comprising such strains, are described. Further, E. coli strains expressing unnatural combination of at least two different CFs, e.g., CFA/I+CS2, CFA/I+CS6, or CS2+CS4 are disclosed.
    Type: Application
    Filed: August 15, 2011
    Publication date: April 5, 2012
    Inventors: Michael Lebens, Ann-Mari Svennerholm, Joshua Tobias
  • Patent number: 8088621
    Abstract: The instant invention provides methods and compositions for generating recombinant adenoviral vectors. The invention also provides kits comprising for the generation of recombinant adenoviral vectors.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: January 3, 2012
    Assignee: The Johns Hopkins University
    Inventors: Ronald Rodriguez, Shawn Edward Lupold, Wasim Haider Chowdhury, Tarana A. Kudrolli
  • Patent number: 8071339
    Abstract: The present invention relates to a mutant bacterial PRPP synthetase which is resistant to feedback by purine nucleotides, and a method for producing L-histidine using the bacterium of the Enterobacteriaceae family wherein the L-amino acid productivity of said bacterium is enhanced by use of the PRPP synthetase which is resistant to feedback by purine nucleotides, coded by the mutant prsA gene.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Elena Vitalievna Klyachko, Rustem Saidovich Shakulov, Yuri Ivanovich Kozlov
  • Patent number: 8067239
    Abstract: The present invention features homologous recombination methods and systems. The methods and systems promote highly efficient homologous recombination in cells (e.g., in prokaryotic cells). The methods and systems are useful, for example, in pharmaceutical drug development, vaccine development and cloning.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: November 29, 2011
    Assignee: University of Massachusetts
    Inventor: Kenan C. Murphy
  • Patent number: 8029789
    Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
    Type: Grant
    Filed: November 13, 2004
    Date of Patent: October 4, 2011
    Assignee: Hanmi Holdings Co., Ltd.
    Inventors: Sung Youb Jung, Jin Sun Kim, Young Jin Park, Ki-Doo Choi, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 8030028
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: October 4, 2011
    Assignee: The Scripps Research Institute
    Inventors: J. Christopher Anderson, Ning Wu, Stephen Santoro, Peter G. Schultz
  • Patent number: 8008041
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: August 30, 2011
    Assignee: The Scripps Research Institute
    Inventors: Lital Alfonta, Peter G. Schultz, Zhiwen Zhang
  • Patent number: 8003362
    Abstract: The invention provides methods and nucleic acid constructs to express clostripain. The source of the coding region for recombinantly expressed clostripain is Clostridium histolyticum.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: August 23, 2011
    Assignee: Medtronic Inc.
    Inventors: Fred W. Wagner, Peng Luan, Yuannan Xia, Barton Holmquist
  • Patent number: 7935511
    Abstract: Methods of increasing yields of succinate using aerobic culture methods and a multi-mutant E. coli strain are provided. Also provided is a mutant strain of E. coli that produces high amounts of succinic acid.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: May 3, 2011
    Assignee: Rice University
    Inventors: Ka-Yiu San, George N. Bennett, Henry Lin
  • Patent number: 7919282
    Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the cpxR gene.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: April 5, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Konstantin Vyacheslavovich Rybak, Aleksandra Yurievna Skorokhodova, Elvira Borisovna Voroshilova, Tatyana Viktorovna Leonova
  • Patent number: 7915025
    Abstract: The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: March 29, 2011
    Assignees: The Scripps Research Institute, The Regents of the University of California
    Inventors: Peter Schultz, Lei Wang, John Christopher Anderson, Jason W. Chin, David R. Liu, Thomas J. Magliery, Eric Meggers, Ryan Aaron Mehl, Miro Pastrnak, Stephen William Santoro, Zhiwen Zhang
  • Publication number: 20110028423
    Abstract: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect choline acetyltransferase; a method for assaying pesticidal activity of a test substance, which comprises measuring the activity of a choline acetyltransferase in a reaction system in which the choline acetyltransferase contacts with a test substance, and the like.
    Type: Application
    Filed: November 21, 2008
    Publication date: February 3, 2011
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Junko Otsuki, Marc Van De Craen, Annelies Roobrouck, Guy Nys, Bert Demey
  • Publication number: 20110020938
    Abstract: An object is to provide a means of highly producing an oxalate decarboxylase originating in a microorganism. A recombinant expression plasmid vector, which contains an ?-amylase promoter belonging to the genus Bacillus and an oxalate decarboxylase gene originating in a microorganism that is provided under the control of the promoter, is constructed. A host bacterium is transformed with this vector to prepare an oxalate decarboxylase producing bacterium. A recombinant oxalate decarboxylase is produced by culturing the producing bacterium and then recovering the oxalate decarboxylase thus produced.
    Type: Application
    Filed: November 26, 2008
    Publication date: January 27, 2011
    Applicant: AMANO ENZYME INC.
    Inventors: Takahumi Koyama, Yuzo Kojima, Kenji Kojima, Masashi Minoda
  • Patent number: 7846694
    Abstract: Provided is a method of producing a template DNA used for protein synthesis comprising a step of amplifying a linear double-stranded DNA by polymerase chain reaction (PCR), by using a reaction solution comprising a first double-stranded DNA fragment comprising a sequence coding for a protein or a portion thereof, a second double-stranded DNA fragment comprising a sequence overlapping with the 5? terminal region of the first DNA fragment, a third double-stranded DNA fragment comprising a sequence overlapping with the 3? terminal region of the first DNA fragment, a sense primer which anneals with the 5? terminal region of the second DNA fragment, and an anti-sense primer which anneals with the 3? terminal region of the third DNA fragment, wherein the second DNA fragment comprises a regulatory sequence for transcription and translation of a gene, and the concentrations of the second DNA fragment and the third DNA fragment in the reaction solution each range from 5 to 2,500 pmol/L.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: December 7, 2010
    Assignee: Riken
    Inventors: Yoko Motoda, Takashi Yabuki, Takanori Kigawa, Shigeyuki Yokoyama
  • Patent number: 7820443
    Abstract: The invention relates to a fast method of transforming competent cells, comprising: a. mixing a plasmid DNA with the competent cells suspending within ionic solution to form a mixture; b. plating the mixture on a warm selective medium; and c. culturing the mixture on the medium; wherein the ionic solution comprises divalent cation selected from the group consisting of Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Cd2+, Fe2+, Sr2+ and Co2+, and provided that the ionic solution does not include Ca2+ alone.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: October 26, 2010
    Assignee: Yeastern Biotech Co., Ltd.
    Inventor: Tzu-Chih Chen
  • Patent number: 7811801
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: October 12, 2010
    Assignee: The Scripps Research Institute
    Inventors: Lital Alfonta, Peter G. Schultz, Zhiwen Zhang
  • Patent number: 7794726
    Abstract: The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version of the enzyme from E. corrodens and induces production of antibodies that inhibit the activity of the lysine decarboxylase enzyme in the oral cavity. The recombinant lysine decarboxylase mutant, in one version, comprises a mutation at residue 365 or at other locations within the active site, and in a preferred embodiment is produced from E. coli in large amounts and to form inclusion bodies. The purified inclusion bodies can then be used in the vaccine composition to induce in vivo production of antibodies that inhibit the activity of native E. corrodens lysine decarboxylase.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 14, 2010
    Assignee: The Boards of Regents of the University of Oklahoma
    Inventor: Martin Levine
  • Patent number: 7790426
    Abstract: The invention relates to sesquiterpene synthases and methods of their production and use. In one embodiment, the invention provides nucleic acids comprising a nucleotide sequence as described herein that encodes for at least one sesquiterpene synthases. In a further embodiment, the invention also provides for sesquiterpene synthases and methods of making and using these enzymes. For example, sesquiterpene synthases of the invention may be used to convert farnesyl-pyrophosphate to various oxygenated and aliphatic sesquiterpenes including valencene, bicyclo-germacrene, cubebol and delta-cadinene.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: September 7, 2010
    Assignee: Firmenich SA
    Inventors: Michel Schalk, Anthony Clark
  • Patent number: 7790847
    Abstract: The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the unnatural amino acid phenylselenocysteine into proteins produced in eubacterial host cells such as E. coli. The invention provides, for example but not limited to, novel orthogonal aminoacyl-tRNA synthetases, polynucleotides encoding the novel synthetase molecules, methods for identifying and making the novel synthetases, methods for producing proteins containing the unnatural amino acid phenylselenocysteine and translation systems. The invention further provides methods for producing modified proteins (e.g., lipidated proteins) through targeted modification of the phenylselenocysteine residue in a protein.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: September 7, 2010
    Assignee: The Scripps Research Institute
    Inventors: Jiangyun Wang, Peter G. Schultz
  • Patent number: 7781190
    Abstract: This invention provides a method for combining overlapping DNA molecules comprising: (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) tagging the first DNA fragment with a selectable marker; (c) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (d) linearizing the DNA-vector complex; and (e) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule; and (f) removing the selectable marker, thereby generating a combined DNA molecule. The invention further provides a vector for retrieving and inserting a selected DNA molecule into a target DNA molecule.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: August 24, 2010
    Assignee: The University of Hong Kong
    Inventors: Jian-Dong Huang, Xin-Mei Zhang, Julian Alexander Tanner